HomeCompareGSGTF vs SBUX

GSGTF vs SBUX: Dividend Comparison 2026

GSGTF yields 1052.08% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GSGTF wins by $29376466.39M in total portfolio value
10 years
GSGTF
GSGTF
● Live price
1052.08%
Share price
$0.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29376466.55M
Annual income
$24,748,961,707,406.69
Full GSGTF calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — GSGTF vs SBUX

📍 GSGTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGSGTFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GSGTF + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GSGTF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GSGTF
Annual income on $10K today (after 15% tax)
$89,426.62/yr
After 10yr DRIP, annual income (after tax)
$21,036,617,451,295.69/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, GSGTF beats the other by $21,036,617,395,331.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GSGTF + SBUX for your $10,000?

GSGTF: 50%SBUX: 50%
100% SBUX50/50100% GSGTF
Portfolio after 10yr
$14688233.35M
Annual income
$12,374,480,886,623.41/yr
Blended yield
84.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

GSGTF
No analyst data
Altman Z
-9.7
Piotroski
2/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GSGTF buys
0
SBUX buys
0
No recent congressional trades found for GSGTF or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGSGTFSBUX
Forward yield1052.08%2.75%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$29376466.55M$157.5K
Annual income after 10y$24,748,961,707,406.69$65,840.13
Total dividends collected$29025351.72M$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: GSGTF vs SBUX ($10,000, DRIP)

YearGSGTF PortfolioGSGTF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$115,908$105,207.79$11,107$407.21+$104.8KGSGTF
2$1,263,685$1,139,663.68$12,512$626.87+$1.25MGSGTF
3$12,964,467$11,612,324.37$14,366$978.69+$12.95MGSGTF
4$125,211,982$111,340,001.64$16,929$1,557.50+$125.20MGSGTF
5$1,138,959,685$1,004,982,865.01$20,658$2,543.80+$1138.94MGSGTF
6$9,762,216,739$8,543,529,875.74$26,406$4,302.22+$9762.19MGSGTF
7$78,882,996,544$68,437,424,632.64$35,877$7,622.00+$78882.96MGSGTF
8$601,231,379,017$516,826,572,714.96$52,741$14,352.64+$601231.33MGSGTF
9$4,324,770,879,470$3,681,453,303,922.24$85,676$29,243.03+$4324770.79MGSGTF
10$29,376,466,548,439$24,748,961,707,406.69$157,513$65,840.13+$29376466.39MGSGTF

GSGTF vs SBUX: Complete Analysis 2026

GSGTFStock

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.

Full GSGTF Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this GSGTF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GSGTF vs SCHDGSGTF vs JEPIGSGTF vs OGSGTF vs KOGSGTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.